Eosinophilic granulomatosis with polyangiitis, first described in the early 1950s by Dr. Jacob Churg and Dr. Lotte Strauss (hence the original name, the Churg–Strauss syndrome), is a rare condition that can affect many organ systems, most commonly the lung, with the majority of patients presenting with asthma symptoms, occasionally complicated by the fleeting presence of pulmonary infiltrates.1 Many different treatments have been tried for eosinophilic granulomatosis with polyangiitis, with limited or no success, and systemic glucocorticoids are the standard treatment for both eosinophilic granulomatosis with polyangiitis1 and severe refractory asthma.2 The predominance of eosinophils in the peripheral blood and tissues . . .